Martin Hegen

Pfizer (United States) — United States

Medicine · Health Sciences

33h-index4.4kcitations65works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(22), Rheumatoid Arthritis Research and Therapies(16), Monoclonal and Polyclonal Antibodies Research(14), Peptidase Inhibition and Analysis(13), Cell Adhesion Molecules Research(6)

Publications65 total

Ligand non-competitive GITR antibody prevents formation of the obligatory signal-triggering GITRL: GITR stoichiometry
Scientific Reports·2025Open Access
Cure as a treatment target in rheumatoid arthritis and systemic sclerosis—achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration
Annals of the Rheumatic Diseases·2024· 4 citedOpen Access
A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6+ T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation
Journal of Pharmacology and Experimental Therapeutics·2023· 20 citedOpen Access
RORγt inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating γδ-T cells
Lara D. Veeken·2023· 24 citedOpen Access
The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial
Arthritis & Rheumatology·2021· 86 citedOpen Access
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
Journal of Medicinal Chemistry·2020· 72 citedOpen Access
Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences
Scientific Reports·2020· 11 citedOpen Access
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1
Bioorganic & Medicinal Chemistry·2020· 21 citedOpen Access
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
Pharmacology Research & Perspectives·2019· 101 citedOpen Access
Anti-IL-13Rα2 therapy promotes recovery in a murine model of inflammatory bowel disease
Mucosal Immunology·2019· 44 citedOpen Access
Discovery of 3-Cyano- <i>N</i> -(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 <i>H</i> -pyrrolo[2,3- <i>b</i> ]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist
Journal of Medicinal Chemistry·2018· 32 citedOpen Access
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( <i>S</i> )-2,2-Difluorocyclopropyl)((1 <i>R</i> ,5 <i>S</i> )-3-(2-((1-methyl-1 <i>H</i> -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
Journal of Medicinal Chemistry·2018· 166 citedOpen Access
Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis
Lara D. Veeken·2018· 31 citedOpen Access
Identification of <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
Journal of Medicinal Chemistry·2018· 162 citedOpen Access
BREACH OF AUTOREACTIVE B-CELL TOLERANCE BY
Data Archiving and Networked Services (DANS)·2017
SAT0030 Breach of autoreactive b-cell tolerance by post-translationally modified foreign proteins
Annals of the Rheumatic Diseases·2017Open Access
Discovery of Clinical Candidate 1-{[(2 <i>S</i> ,3 <i>S</i> ,4 <i>S</i> )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design
Journal of Medicinal Chemistry·2017· 138 citedOpen Access
Breach of autoreactive B cell tolerance by post-translationally modified proteins
Annals of the Rheumatic Diseases·2017· 41 citedOpen Access
02.04 Sensitive spect/ct imaging of synovial fap expression after anti-il-22 treatment in experimental arthritis
Annals of the Rheumatic Diseases·2017
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2<i>S</i>,5<i>R</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
Journal of Medicinal Chemistry·2017· 158 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

James D. Clark(12), Cheryl Nickerson‐Nutter(11), Tsung H. Lin(9), Peter T. Symanowicz(9), Jean‐Baptiste Telliez(8), Martin E. Dowty(8), F.F. Vajdos(7), Mary Ellen Banker(6), Fabien Vincent(6), Xin Yang(6), T. Huizinga(5), René E. M. Toes(5), Jason Jussif(5), Matthew F. Brown(5), John I. Trujillo(5), Catherine M. Ambler(5), James C. Keith(4), Mary Collins(4), Runyu Dong(4), Chikao Morimoto(4)